Brolucizumab

Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM) . Brolucizumab can be used for the research of cancer[1][2].

Product Specifications

CAS Number

[1531589-13-5]

Product Name Alternative

DLX1008; ESBA 1008; RTH258

UNSPSC

12352203

Target

VEGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/brolucizumab.html

Purity

99.90

Solubility

H2O

Smiles

[Brolucizumab]

Molecular Weight

(26.18 kDa)

References & Citations

[1]Szabó E, et, al. Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. J Pharmacol Exp Ther. 2018 May;365 (2) :422-429.|[2]Eason AB, et, al. DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma. PLoS One. 2020 May 14;15 (5) :e0233116.